A study done in 2015 by PharmaExec sought to establish the
A study done in 2015 by PharmaExec sought to establish the value of a BTD. To begin, the inherent beneficial value is 2.5 years earlier approval for a New Molecular Entity (EME) and 3.5 years earlier approval for drugs under Orphan Status or accelerated approval designations. Since the program began in 2012...a total of 130 FDA approvals are split between 19 public companies and 5 private companies.
The average MKT CAP is $138.2 Billion.
The weighted average is $174.1 Billion...obviously suggesting Big Pharma players have the greatest number of BTD's.
The smaller subset of companies... that has only ONE approval totals 17.
The average Valuation of these companies is $8.23 Billion. Some private (4) companies got a BTD on very obscure indications...so a value of $8.0 Billion for a BTD could be reasonable.
A point of interest...ABBVie is # 5 on the list with 11 BTD's and Gilead has 4 BTD's.
The companies acquired After BTD total 12.
ALL the companies with 2 or more BTD's were swallowed up by Big Pharma.
ANY company with 2 or more BTD's would be in the HOT zone for acquisition.
*Market Size is the Determinant in BTD Valuation*
Acadia Pharmaceuticals for example has a Market Cap of $2.86 Billion and trades at $17.80 as of this morning. On the second BTD, it was averaging $50.00 Plus starting in late December 2019 and slid to $17-$18. in early September of this year. The patient population for their drug is 2.4 million...with only half currently being treated.
The slide in PPS is a result of the FDA finding deficiencies... in the application for its psychosis drug Nuplazid, which Acadia is addressing.
"Leronlimab is a PLATFORM technology drug and they could see a minimum of 2-4 BTD's in the coming year. Conservative revenues range from $2.1 Billion to $4.2 Billion exceeding all measures of blockbuster status". "This is clearly one to watch."__Theodore Zucconi, PhD in Chemistry, Masters Certificate in International Finance and Program/Project Management.
38 years in High Tech and Biotech... I wonder Why... he's Long?
19
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Core Lab's Quarter in Review With the kind of resilience that makes a trader's hands shake ever so slightly less over a coffee, Core Laboratories Inc. heads into the fourth quarter of 2026. This isn't your typical Wall Street story, that's for sure. Watching a solid player like Core navigate the bumpy roads of today's volatile market reminds me of a...
Continue Reading
The Legal Rigmarole The market's got its knickers in a twist over AST SpaceMobile, folks. If you've been dabbling in NASDAQ:ASTS between March '25 and mid-July '26, it's time to perk up those ears. The legal eagles at Robbins Geller Rudman & Dowd LLP are rallying the troops for a class action lawsuit with you front and center. Deadline's looming on November 13, 2026, for...
Continue Reading
Shuffling the Deck: Huron Consulting Steps In Just when you thought the index shuffle was settled, along comes an eleventh-hour change. Huron Consulting Group is being welcomed with open arms into the S&P SmallCap 600, booting Supernus Pharmaceuticals to the side. Mark November 3 on your calendars—final scorecards before the trading bell could surprise us all. The S&P...
Continue Reading
Peeling Back the Layers of Stigma On World Psoriasis Day, we're flipping the script from pity parties to real change. IFPA's 'Look Beyond My Skin' campaign is rallying against the stigma choking young folks with psoriasis. You can't deny the massive size of this issue – over 100 million people wrangle with this condition globally. Yet, as many of these warriors are...
Continue Reading
AI Takes Center Stage at Guidewire's Annual Gala Change is constant, but when it comes with a potent mix of AI and insurance, you know things are about to get interesting. Guidewire Software (NYSE: GWRE) is tipping its hat to Beazley, Definity, and RCIS, the standouts at its annual Innovation Awards. Held during their CONNECTIONS Conference in Las Vegas, this year's...
Continue Reading
There's a breath of relief in the air over at Medunik USA, where they're keeping a steady course amidst some choppy waters. Those dealing with urea cycle disorders (UCD) have had their fair share of ups and downs, but Pheburane® isn’t going anywhere anytime soon. Medunik USA Holds the Line So, picture yourself in the shoes of a patient battling a rare urea cycle...
Continue Reading
Weathering the Storm: A New Chapter for Jamaica It's been nearly a year since Hurricane Melissa hit, and Jamaica is proving that it won't be pushed around by nature's whims. The island's tourism industry, once battered, is now showing remarkable resilience. With hotels and villas reopening and shaking off the dust, it's safe to say Jamaica is back on its feet, and it's...
Continue Reading
Streamlining Insurance for Healthcare Professionals Here's one for the books in the insurance world: Corgi Insurance is stepping up to spare healthcare practices from the headache of getting medical malpractice coverage. This is more than just insurance talk; it's about time someone carved out a path through the labyrinth of medical malpractice policies. Healthcare folks...
Continue Reading
Veterinary Implants Market: A Growth Tale Something's stirring in the veterinary world, my friend. The Veterinary Implants Devices Market is hitting some serious strides, and we're looking at a valuation touching nearly $0.98 billion by 2031. If you're eyeing the veterinary sector, it's time to sharpen those pencils and take notes on where the trend winds are blowing....
Continue Reading
MidCap Financial's Merger Sparks Legal Action Nobody expects their investments to end up in a courtroom drama, but here we are. MidCap Financial Investment Corporation (NASDAQ: MFIC) is under the microscope, thanks to attorney Juan Monteverde's M&A Class Action Firm. From their perch in the Empire State Building, Monteverde & Associates, celebrated as a top dog in the ISS...
Continue Reading
Top 5 Most Recently Viewed Articles
A Remarkable Achievement for PureSoftware PureSoftware, a proud subsidiary of Happiest Minds, has achieved a significant milestone at the IBSi Digital Banking Awards 2025. The company received two prestigious honors for its flagship platform, Arttha, which is recognized for its excellence in digital lending and innovative wallet solutions. Arttha's Distinction in Digital...
Continue Reading
TruTrade: Elevating Retail Trading to New Heights TruTrade has recently launched the TruTrade Private Client Tier, a transformative platform aimed at enhancing the trading experience for advanced retail traders. This premium offering is tailored for those seeking hedge-fund-level diversification and execution quality in the competitive landscape of trading. Meeting the...
Continue Reading
Insights into HealthStream's Upcoming Earnings Report HealthStream (NASDAQ: HSTM) is set to release its quarterly earnings report shortly. Investors are keenly awaiting the details as they speculate on its performance. Analysts are forecasting an earnings per share (EPS) of $0.12 for the upcoming quarter. The excitement surrounding HealthStream's announcement suggests...
Continue Reading
Davidson Hospitality Group Enters Exciting New Partnership Davidson Hospitality Group, a renowned hospitality management company, has recently revealed an exciting partnership with Nautic Partners. This significant move comes as the company celebrates its milestone anniversary and aims to strengthen its market position further. Overview of Davidson Hospitality Group...
Continue Reading
Understanding the Current Situation at Firefly Aerospace Inc. Firefly Aerospace Inc. (NASDAQ: FLY), a leading innovator in the space industry, is currently facing a class action lawsuit that has raised significant concerns among its shareholders. This lawsuit has been initiated by a shareholder on behalf of a group that purchased Firefly's stock during a defined period....
Continue Reading